Risk of hip fracture in patients on hemodialysis versus peritoneal dialysis: A meta-analysis of observational studies.


Journal

Journal of evidence-based medicine
ISSN: 1756-5391
Titre abrégé: J Evid Based Med
Pays: England
ID NLM: 101497477

Informations de publication

Date de publication:
May 2019
Historique:
received: 27 10 2018
accepted: 31 12 2018
pubmed: 1 2 2019
medline: 24 12 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

Bone and mineral metabolism disorders are common among end-stage renal disease (ESRD) patients, which could lead to hip fracture. It is unclear whether the hip fracture risk is different among patients on hemodialysis (HD) versus peritoneal dialysis (PD). This meta-analysis was conducted to evaluate the hip fracture risk in ESRD patients on HD, when compared to PD. A literature review was conducted in EMBASE, MEDLINE, and Cochrane databases through January 31, 2018 to identify studies that appraised the rate or risk of hip fracture among patients on HD, when compared to PD. Effect estimates from the individual studies were derived and consolidated utilizing random-effect, generic inverse variance approach of DerSimonian and Laird. Five cohort studies with 1 276 677 ESRD patients were enrolled. HD status was associated with a significantly higher risk of hip fracture with the pooled odds ratio (OR) of 1.61 (95% confidence interval [CI] 1.50-1.73, I Among ESRD patients, HD status is associated with a 61% higher risk of hip fracture compared to PD.

Sections du résumé

BACKGROUND BACKGROUND
Bone and mineral metabolism disorders are common among end-stage renal disease (ESRD) patients, which could lead to hip fracture. It is unclear whether the hip fracture risk is different among patients on hemodialysis (HD) versus peritoneal dialysis (PD). This meta-analysis was conducted to evaluate the hip fracture risk in ESRD patients on HD, when compared to PD.
METHODS METHODS
A literature review was conducted in EMBASE, MEDLINE, and Cochrane databases through January 31, 2018 to identify studies that appraised the rate or risk of hip fracture among patients on HD, when compared to PD. Effect estimates from the individual studies were derived and consolidated utilizing random-effect, generic inverse variance approach of DerSimonian and Laird.
RESULTS RESULTS
Five cohort studies with 1 276 677 ESRD patients were enrolled. HD status was associated with a significantly higher risk of hip fracture with the pooled odds ratio (OR) of 1.61 (95% confidence interval [CI] 1.50-1.73, I
CONCLUSIONS CONCLUSIONS
Among ESRD patients, HD status is associated with a 61% higher risk of hip fracture compared to PD.

Identifiants

pubmed: 30701673
doi: 10.1111/jebm.12341
doi:

Types de publication

Comparative Study Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-104

Informations de copyright

© 2019 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.

Auteurs

Boonphiphop Boonpheng (B)

Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee.

Charat Thongprayoon (C)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

Michael A Mao (MA)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

Karn Wijarnpreecha (K)

Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Jacksonville, Florida.

Tarun Bathini (T)

Department of Internal Medicine, University of Arizona, Tucson, Arizona.

Wisit Kaewput (W)

Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.

Patompong Ungprasert (P)

Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Wisit Cheungpasitporn (W)

Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH